These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32416631)

  • 1. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
    Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
    Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
    Gabr A; Abouchaleh N; Ali R; Vouche M; Atassi R; Memon K; Asadi AA; Baker T; Caicedo JC; Desai K; Fryer J; Hickey R; Abeccassis M; Habib A; Hohlastos E; Ganger D; Kulik L; Lewandowski RJ; Riaz A; Salem R
    Eur J Radiol; 2017 Aug; 93():100-106. PubMed ID: 28668402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
    Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
    J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
    Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
    Salem R; Gabr A; Riaz A; Mora R; Ali R; Abecassis M; Hickey R; Kulik L; Ganger D; Flamm S; Atassi R; Atassi B; Sato K; Benson AB; Mulcahy MF; Abouchaleh N; Asadi AA; Desai K; Thornburg B; Vouche M; Habib A; Caicedo J; Miller FH; Yaghmai V; Kallini JR; Mouli S; Lewandowski RJ
    Hepatology; 2018 Oct; 68(4):1429-1440. PubMed ID: 29194711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
    Salem R; Johnson GE; Kim E; Riaz A; Bishay V; Boucher E; Fowers K; Lewandowski R; Padia SA
    Hepatology; 2021 Nov; 74(5):2342-2352. PubMed ID: 33739462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.
    Ettorre GM; Levi Sandri GB; Laurenzi A; Colasanti M; Meniconi RL; Lionetti R; Santoro R; Lepiane P; Sciuto R; Pizzi G; Cianni R; Golfieri R; D'Offizi G; Pellicelli AM; Antonini M; Vennarecci G
    World J Surg; 2017 Jan; 41(1):241-249. PubMed ID: 27495316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
    Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
    Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver-Directed Combined Radiation Therapy for Downstaging Beyond-Milan Hepatocellular Carcinoma to Liver Transplantation.
    Kim J; Kim YT; Lee JG; Han DH; Joo DJ; Kim DY; Seong J
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1171-1178. PubMed ID: 38364951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis.
    Barakat O; Wood RP; Ozaki CF; Ankoma-Sey V; Galati J; Skolkin M; Toombs B; Round M; Moore W; Mieles L
    Liver Transpl; 2010 Mar; 16(3):289-99. PubMed ID: 20209588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
    Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
    Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma.
    Villalobos A; Wagstaff W; Guo M; Zhang J; Bercu Z; Whitmore MJ; Cristescu MM; Majdalany BS; Wedd J; Akce M; Magliocca J; Kokabi N
    Can J Gastroenterol Hepatol; 2021; 2021():9926704. PubMed ID: 34336728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
    Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.
    Kulik LM; Atassi B; van Holsbeeck L; Souman T; Lewandowski RJ; Mulcahy MF; Hunter RD; Nemcek AA; Abecassis MM; Haines KG; Salem R
    J Surg Oncol; 2006 Dec; 94(7):572-86. PubMed ID: 17048240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.
    Lei JY; Yan LN; Wang WT
    World J Gastroenterol; 2013 Jul; 19(27):4400-8. PubMed ID: 23885153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.
    Dabrowiecki A; Sankhla T; Shinn K; Bercu ZL; Ermentrout M; Shaib W; Cardona K; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1006-1014. PubMed ID: 32367230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
    Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ
    Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment.
    Radunz S; Treckmann J; Baba HA; Best J; Müller S; Theysohn JM; Paul A; Benkö T
    Ann Transplant; 2017 Apr; 22():215-221. PubMed ID: 28408731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
    Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.